TP53 and neoplasm: Different HDACIs, including the short chain fatty acid butyrate and hydroxamic acid SAHA (vorinostat), have been shown to promote wild-type p53-dependent apoptosis [33] and to sensitise BRAFV600E-mutated tumour cells to the effects of BRAF inhibitors [34,35].